Christopher P Cannon Selected Research

Unstable Angina

8/2018	Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome.
12/2016	Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.
2/2016	Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.
9/2015	On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study).
6/2015	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
5/2015	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
8/2014	Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
10/2013	Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
10/2013	Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy.
3/2013	Prognostic evaluation of catalytic iron in patients with acute coronary syndromes.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christopher P Cannon Research Topics

Disease

236	Acute Coronary Syndrome 10/2021 - 02/2002
226	Myocardial Infarction 07/2022 - 03/2002
95	Stroke (Strokes) 01/2022 - 07/2003
86	Hemorrhage 01/2022 - 12/2002
77	Heart Failure 10/2022 - 03/2002
72	ST Elevation Myocardial Infarction 08/2021 - 03/2002
67	Cardiovascular Diseases (Cardiovascular Disease) 10/2022 - 04/2002
58	Type 2 Diabetes Mellitus (MODY) 10/2022 - 12/2007
54	Unstable Angina 08/2018 - 10/2002
52	Atrial Fibrillation 10/2022 - 09/2004
50	Thrombosis (Thrombus) 07/2022 - 07/2002
45	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 11/2002
42	Infections 01/2021 - 04/2002
38	Coronary Disease (Coronary Heart Disease) 01/2020 - 02/2003
31	Non-ST Elevated Myocardial Infarction 01/2017 - 10/2002
23	Hypertension (High Blood Pressure) 07/2022 - 02/2003
20	Diabetes Mellitus 01/2022 - 10/2002
19	Inflammation (Inflammations) 12/2021 - 02/2003
18	Chronic Renal Insufficiency 10/2022 - 01/2010
18	Infarction (Infarctions) 08/2009 - 04/2002
16	Ischemic Stroke 10/2022 - 09/2004
15	Neoplasms (Cancer) 12/2021 - 12/2003
15	Atherosclerosis 01/2020 - 02/2003
12	Atherosclerotic Plaque (Atheroma) 12/2021 - 06/2004
11	Peripheral Arterial Disease 01/2022 - 08/2004
11	Renal Insufficiency (Renal Failure) 08/2021 - 02/2003
11	Dyslipidemias (Dyslipidemia) 01/2021 - 11/2007
11	Ischemia 01/2014 - 06/2002
10	Hypercholesterolemia 01/2022 - 04/2003
10	Left Ventricular Dysfunction 05/2017 - 01/2003
9	Albuminuria 01/2021 - 10/2010
9	Obesity 12/2019 - 03/2006
8	Kidney Diseases (Kidney Disease) 01/2022 - 12/2017
7	Body Weight (Weight, Body) 01/2022 - 03/2005
7	Vascular Diseases (Vascular Disease) 01/2017 - 04/2003
7	Arthritis (Polyarthritis) 12/2012 - 08/2006
7	Osteoarthritis 06/2011 - 08/2006

Drug/Important Bio-Agent (IBA)

100	Clopidogrel (Plavix)FDA Link 08/2021 - 10/2002
85	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 04/2004
65	LipidsIBA 06/2021 - 04/2003
64	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2021 - 09/2002
54	TicagrelorIBA 08/2021 - 11/2007
46	Atorvastatin (Lipitor)FDA Link 01/2018 - 04/2002
43	Pravastatin (Pravachol)FDA LinkGeneric 01/2018 - 04/2002
41	LDL CholesterolIBA 07/2022 - 10/2004
41	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2002
36	oxidized low density lipoproteinIBA 01/2022 - 12/2003
32	Tirofiban (Aggrastat)FDA Link 11/2020 - 07/2002
32	C-Reactive ProteinIBA 12/2018 - 04/2002
26	Ezetimibe (Zetia)FDA Link 10/2021 - 08/2014
23	Simvastatin (Zocor)FDA LinkGeneric 10/2021 - 12/2005
21	omega-Chloroacetophenone (Mace)IBA 01/2022 - 12/2009
21	Warfarin (Coumadin)FDA LinkGeneric 12/2021 - 01/2009
20	Dabigatran FDA Link 01/2022 - 11/2010
19	darapladibIBA 12/2021 - 10/2010
19	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2020 - 02/2002
18	CanagliflozinIBA 10/2022 - 12/2017
17	CreatinineIBA 01/2022 - 10/2003
17	AnticoagulantsIBA 01/2021 - 12/2007
15	alogliptinIBA 01/2020 - 10/2011
15	Glycoproteins (Glycoprotein)IBA 07/2016 - 12/2002
15	Heparin (Liquaemin)FDA LinkGeneric 01/2011 - 09/2002
14	Pharmaceutical PreparationsIBA 01/2021 - 03/2002
14	TroponinIBA 09/2017 - 07/2002
13	Simvastatin Drug Combination Ezetimibe (Vytorin)FDA Link 10/2021 - 11/2008
13	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 12/2016 - 06/2004
12	HDL CholesterolIBA 07/2022 - 01/2007
12	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 06/2006
12	orbofibanIBA 10/2006 - 12/2002
10	Sodium-Glucose Transporter 2 InhibitorsIBA 05/2022 - 01/2019
10	ertugliflozinIBA 05/2022 - 12/2018
10	pro-brain natriuretic peptide (1-76)IBA 01/2021 - 04/2008
10	Troponin IIBA 01/2018 - 04/2002
9	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 01/2022 - 02/2014
9	alirocumabIBA 09/2020 - 06/2015
9	EtoricoxibIBA 12/2012 - 08/2006
9	N(2)-(3-trifluoromethylphenyl)guanineIBA 05/2008 - 04/2002
8	Sodium-Glucose Transport ProteinsIBA 01/2022 - 01/2019
8	Vitamin K FDA Link 01/2021 - 10/2017
8	Growth Differentiation Factor 15IBA 12/2019 - 01/2011
8	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 01/2018 - 04/2006
8	Angiotensin Receptor AntagonistsIBA 12/2016 - 06/2009
8	Diclofenac (SR 38)FDA LinkGeneric 12/2012 - 08/2006
7	Troponin T (Troponin T1)IBA 02/2017 - 07/2002
7	Triglycerides (Triacylglycerol)IBA 09/2015 - 01/2007
7	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2014 - 08/2006
7	RimonabantIBA 04/2008 - 03/2006
7	Platelet Membrane Glycoprotein IIbIBA 03/2008 - 10/2002
6	DiureticsIBA 01/2021 - 04/2013
6	CholesterolIBA 01/2020 - 12/2004
6	Hypoglycemic Agents (Hypoglycemics)IBA 01/2020 - 10/2011
6	Cystatin CIBA 12/2019 - 01/2017

Therapy/Procedure

277	Therapeutics 07/2022 - 03/2002
71	Percutaneous Coronary Intervention 07/2022 - 04/2002
30	Stents 07/2022 - 05/2006
27	Thrombolytic Therapy 08/2009 - 10/2002
26	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2019 - 12/2002
24	Patient Readmission 01/2017 - 09/2002
21	Secondary Prevention 01/2021 - 02/2004
8	Conservative Treatment 09/2017 - 07/2002